Scholarlink

Background <p>We investigated the safety and efficacy of laparoscopic gastrectomy (LG) in patients with locally advanced gastric cancer who underwent neoadjuvant chemotherapy (NAC).</p> Methods <p>This study included 247 consecutive patients with advanced gastric cancer who underwent NAC followed by gastrectomy between 2007 and 2017 at one of six institutions. The patients were divided into the open gastrectomy (OG) and LG groups. The short- and long-term outcomes in both groups were investigated after propensity score matching.</p> Results <p>After propensity score matching, 72 pairs of patients were selected. The baseline characteristics were not significantly different after matching. Compared with the OG group, the LG group had a significantly longer operative time (360 vs. 305&#xa0;min, <i>P</i> = 0.002) and less intraoperative blood loss (271 vs. 652&#xa0;mL, <i>P</i> &lt; 0.001). The LG group had more harvested lymph nodes than the OG group (57.4 vs. 45.1, <i>P</i> &lt; 0.001). The frequency of Clavien–Dindo grade ≥ 2 postoperative complications was not significantly different (26% vs. 22%, <i>P</i> = 0.698). The interval between surgery and postoperative chemotherapy was significantly shorter in the LG group (48.7 vs. 68.6&#xa0;days, <i>P</i> = 0.048). The 5-year overall survival rates in the OG and LG groups were 54.4% and 53.5%, respectively. The overall survival was similar between the two groups (<i>P</i> = 0.773). No significant differences were observed between the two groups in terms of the type of recurrence, including lymph node, hematogenous, and peritoneal recurrences (<i>P</i> = 1.000, <i>P</i> = 1.000, and <i>P</i> = 0.686, respectively).</p> Conclusions <p>Based on both short- and long-term results, LG is a potential therapeutic option for patients with gastric cancer who undergo NAC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of laparoscopic and open gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a propensity score matching analysis

  • 期刊论文

  • 发表日期：

    2025年2月13日

查看全文
  • Keijiro Sugimura,
  • Masaaki Motoori,
  • Kishi Kentaro,
  • Kazuyoshi Yamamoto,
  • Atsushi Takeno,
  • Hisashi Hara,
  • Takuya Hamakawa,
  • Kohei Murakami,
  • Yujiro Nakahara,
  • Toru Masuzawa,
  • Takeshi Omori,
  • Yukinori Kurokawa,
  • Kazumasa Fujitani,
  • Yuichiro Doki

摘要

Background

We investigated the safety and efficacy of laparoscopic gastrectomy (LG) in patients with locally advanced gastric cancer who underwent neoadjuvant chemotherapy (NAC).

Methods

This study included 247 consecutive patients with advanced gastric cancer who underwent NAC followed by gastrectomy between 2007 and 2017 at one of six institutions. The patients were divided into the open gastrectomy (OG) and LG groups. The short- and long-term outcomes in both groups were investigated after propensity score matching.

Results

After propensity score matching, 72 pairs of patients were selected. The baseline characteristics were not significantly different after matching. Compared with the OG group, the LG group had a significantly longer operative time (360 vs. 305 min, P = 0.002) and less intraoperative blood loss (271 vs. 652 mL, P < 0.001). The LG group had more harvested lymph nodes than the OG group (57.4 vs. 45.1, P < 0.001). The frequency of Clavien–Dindo grade ≥ 2 postoperative complications was not significantly different (26% vs. 22%, P = 0.698). The interval between surgery and postoperative chemotherapy was significantly shorter in the LG group (48.7 vs. 68.6 days, P = 0.048). The 5-year overall survival rates in the OG and LG groups were 54.4% and 53.5%, respectively. The overall survival was similar between the two groups (P = 0.773). No significant differences were observed between the two groups in terms of the type of recurrence, including lymph node, hematogenous, and peritoneal recurrences (P = 1.000, P = 1.000, and P = 0.686, respectively).

Conclusions

Based on both short- and long-term results, LG is a potential therapeutic option for patients with gastric cancer who undergo NAC.